LAUREN CRANFILL: Open Payments
NPI 1720521065 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$800 in 47 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $800
Food & beverage: $800
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $223 |
| Neurocrine BioSciences, Inc. | 3 | $186 |
| ABIOMED | 3 | $91 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $33 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: CAPLYTA, INGREZZA, REXULTI, Auvelity, TRINTELLIX, AUSTEDO XR, Jornay PM, SPRAVATO.
Industry payments across VA — which companies pay providers there.
